

BIOMARIN PHARMACEUTICAL INC  
Form 8-K  
June 04, 2004

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

---

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2004

---

## BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction)

000-26727  
(Commission File Number)

68-0397820  
(IRS Employer

of incorporation or organization)

Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California  
(Address of principal executive offices)

94949  
(Zip Code)

Registrant's telephone number, including area code: (415) 506-6700

**Not Applicable**

(Former name or former address, if changed since last report)

---

**Item 5. Other Events.**

On June 3, 2004, BioMarin Pharmaceutical Inc. (the Registrant ), issued a press release regarding the announcement of the data and results of its Phase 3 trial of Aryplase for the treatment of MPS VI. The Registrant s press release issued on June 3, 2004 is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.**

- (a) Financial Statements of Business Acquired.

Not Applicable.

- (b) Pro Forma Financial Information.

Not Applicable.

- (c) Exhibits.

Exhibit 99.1 Press Release of the Registrant dated June 3, 2004.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.,  
a Delaware corporation

Date: June 3, 2004

By: **/s/ Louis Drapeau**

---

Louis Drapeau

Chief Financial Officer

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release of the Registrant dated June 3, 2004